

New Brand Drug Pipeline

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Nalmefene Injection	Opioid Agonist	Opioid Overdose	Launch pending. Approved February 8, 2022.
Baclofen Granules (Lyvispah [™])	Muscle Relaxant	Muscle Spasms	Launch pending. Approved November 22, 2021.
Buprenorphine Depot Injection (Brixadi [™])	Opioid Agonist	Treatment of Opioid Addiction	FDA review pending.
Oxycodone (Aximris XR [™])	Opioid Analgesic – Extended Release	Pain	FDA review pending.
Meloxicam/Rizatriptan	NSAID/Serotonin Agonist	Migraine Headache	FDA review pending.

Generic Pipeline

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Vilazodone (Viibryd [®])	Antidepressant	Depression	Patent set to expire June 2022.
Dabigatran (Pradaxa [®])	Anticoagulant	Treatment/Prophylaxis of Deep Vein Thrombosis	First patent set to expire December 2021. Generic anticipated June 2022.
Oxycodone HCl (Oxaydo [®])	Opioid Agonist	Pain	Generic exclusivity anticipated in 2022.
Apixaban (Eliquis [®])	Anticoagulant	Treatment/Prophylaxis of Deep Vein Thrombosis	Generics approved December 23, 2019, but settlements expected to delay launch for at least a few years.

Report

Monthly New Drug and First Time Generic April 2022



Available in the Last 12 Months

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Naloxone Injection (Zimhi ™)	Opioid Antagonist	Opioid Overdose	March 2022
Celecoxib/Tramadol (Seglentis ®)	NSAID/Opioid Agonist	Pain	March 2022
Baclofen Oral Suspension (Fleqsuvy ™)	Muscle Relaxant	Muscle Spasms	March 2022
Celecoxib Oral Liquid (Elyxyb ™)	NSAID	Migraine Headache Treatment	February 2022
Naloxone Nasal Spray (Kloxxado ™)	Opioid Antagonist	Opioid Overdose	August 2021

Newly Available Generics

Diclofenac Potassium (Zipsor ®) Capsule	NSAID	Pain	March 2022
Naloxone HCl (Narcan ®) Nasal Spray	Opioid Antagonist	Opioid Overdose	December 2021
Zolmitriptan Nasal Spray (Zomig ®)	Serotonin Agonist	Migraine Headache Treatment	November 2021
Nebivolol (Bystolic ®)	Beta Blocker	High Blood Pressure	September 2021
Ibuprofen/Famotidine (Duexis ®)	NSAID/H-2 Receptor Antagonist	Pain/Inflammation	August 2021
Pregabalin Extended Release (Lyrica ® CR)	Anticonvulsant	Neuropathic Pain	April 2021

Discontinuations & Withdrawals

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Hydrocodone ER Capsules (Zohydro ® ER)	Opioid Antagonist	Pain	Manufacturer has stopped distribution and FDA has rescinded approval effective February 2022.